Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B

Bepirovirsen, an antisense oligonucleotide, induces sustained reductions in hepatitis B surface antigen (HBsAg) and HBV DNA to below the lower limit of quantification (

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2024-08
Main Authors: Buti, Maria, Heo, Jeong, Tanaka, Yasuhito, Andreone, Pietro, Atsukawa, Masanori, Cabezas, Joaquín, Chak, Eric, Coffin, Carla S., Fujiwara, Kei, Gankina, Natalya, Gordon, Stuart C., Janczewska, Ewa, Komori, Atsumasa, Lampertico, Pietro, McPherson, Stuart, Morozov, Vyacheslav, Plesniak, Robert, Poulin, Sébastien, Ryan, Pablo, Sagalova, Olga, Sheng, Guoping, Voloshina, Natalya, Xie, Qing, Yim, Hyung Joon, Dixon, Susan, Paff, Melanie, Felton, Leigh, Lee, Maximilian, Greene, Thomas, Lim, Jessica, Lakshminarayanan, Divya, McGonagle, Grant, Plein, Helene, Youssef, Amir S., Elston, Rob, Kendrick, Stuart, Theodore, Dickens
Format: Article
Language:English
Subjects:
antisense oligonucleotide
bepirovirsen
Hepatitis B
pegylated interferon-α-2a
sequential therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bepirovirsen, an antisense oligonucleotide, induces sustained reductions in hepatitis B surface antigen (HBsAg) and HBV DNA to below the lower limit of quantification (
ISSN:0168-8278
1600-0641
1600-0641
DOI:10.1016/j.jhep.2024.08.010